Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The European Society of Cardiology (ESC) has granted Class I recommendation for AstraZeneca's oral antiplatelet medicine Brilique (ticagrelor) in the revised 'Guidelines for Management of Acute Coronary Syndromes (ACS) in patients presenting without persistent ST-segment elevation.'
Subscribe to our email newsletter
According to the revised guidelines, ticagrelor is recommended for all non-ST elevation ACS patients at moderate-to-high risk of ischaemic events, regardless of initial treatment strategy and including those pre-treated with clopidogrel (which should be discontinued when ticagrelor is commenced) (Class 1, level of evidence B).
In addition, the guidelines recommend ticagrelor be considered for initiation or resumption following coronary artery bypass graft (CABG) surgery as soon as it is considered safe (Class IIa, level of evidence B).
The ESC guidelines was given on the basis of review of ticagrelor clinical programme, including results from a study of platelet inhibition and patient outcomes (PLATO) study.
The study results suggested that treating 54 ACS patients with ticagrelor instead of clopidogrel for one year prevented one atherothrombotic event and treating 91 patients prevented one cardiovascular (CV) death, with no increase in overall major/fatal bleeding over the course of one year of treatment.